English, Article edition: Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus Frederick B. Dong; Stephen W. Sorensen; Diane L. Manninen; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94857
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus
Author
  • Frederick B. Dong
  • Stephen W. Sorensen
  • Diane L. Manninen
  • Theodore J. Thompson
  • Venkat Narayan
  • Carlyn E. Orians
  • Edward W. Gregg
  • Richard C. Eastman
  • Erik J. Dasbach
  • William H. Herman
  • Jeffrey M. Newman
  • Andrew S. Narva
  • David J. Ballard
  • Michael M. Engelgau
Physical Description
  • article
Notes
  • Objective: Current guidelines recommend treating patients with type 1 diabetes mellitus with ACE inhibitors after the onset of microalbuminuria. Recent clinical trials have shown ACE inhibitors can affect the development of nephropathy when initiated prior to the onset of microalbuminuria. Our objective is to examine the cost effectiveness of treating adults aged over 20 years with an ACE inhibitor (captopril) immediately following diagnosis of type 1 diabetes versus treating them after the onset of microalbuminuria. Design: Using a semi-Markov model, we calculated four main outcome measures: lifetime direct medical costs (discounted), QALYs, cumulative incidence of end-stage renal disease (ESRD), and number of days of ESRD over a lifetime. Medical costs are in 1999 US dollars. Setting: All analyses were from the viewpoint of a single US payer responsible for all direct medical costs, including screening for microalbuminuria, ACE inhibitor treatment (captopril), management of major diabetic complications, and routine annual medical costs not specific to diabetes. Methods: We applied the model to a hypothetical cohort of 10 Results: We estimated that the incremental cost of early use of captopril for the average adult with type 1 diabetes is $US27 Conclusion: This model, with its underlying assumptions and data, suggests that early treatment with captopril provides modest benefit at reasonable cost effectiveness, from the US single-payer perspective, in the prevention of ESRD compared with delaying treatment until diagnosis of microalbuminuria. Early treatment with other ACE inhibitors will provide similar cost effectiveness if they have equivalent efficacy, compliance and price per dose. Treatment may be considered among patients at age 20 years with new onset of type 1 diabetes. This conclusion is sensitive to the extent that ACE inhibitors delay onset of microalbuminuria. Other factors such as the patient's age and glycaemic level must be considered when deciding to initiate early treatment.
  • ACE-inhibitors, Captopril, Cost-utility, Diabetic-nephropathies
  • RePEc:wkh:phecon:v:22:y:2004:i:15:p:1015-1027
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment